Ph 1 Study Long-acting Interleukin-7, Efineptakin Alfa, to Enhance Immune Reconstitution After PTCy
Phase 1 Study of Long-acting Interleukin-7, Efineptakin Alfa, to Enhance Immune Reconstitution After Post-transplantation Cyclophosphamide
This phase 1, single-center, open-label dose-escalation study will evaluate the safety, tolerability, and immune reconstitution effects of efineptakin alfa (rhIL-7-hyFc, NT-I7) administered after allogeneic hematopoietic cell transplantation (allo-HCT) in participants receiving post-transplantation cyclophosphamide (PTCy)-based graft-versus-host disease prophylaxis.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究連絡先
研究連絡先
- 名前:Maria Urdiales Kouba
- 電話番号:813-745-1218
- メール:Maria.UrdialesKouba@moffitt.org
研究場所
-
-
Florida
-
Tampa、Florida、アメリカ、33612
- 募集
- Moffitt Cancer Center
-
副調査官:
- Melissa Alsina, MD
-
副調査官:
- Lia Perez, MD
-
副調査官:
- Doris Hansen, MD
-
副調査官:
- Rawan Faramand, MD
-
副調査官:
- Hien Liu, MD
-
副調査官:
- Omar Castaneda Puglianini, MD
-
副調査官:
- Michael Jain, MD
-
副調査官:
- Asmita Mishra, MD
-
副調査官:
- Taiga Nishihori, MD
-
副調査官:
- Nelli Bejanyan, MD
-
副調査官:
- Farhad Khimani, MD
-
副調査官:
- Aleksandr Lazaryan, MD
-
副調査官:
- Fabiana Perna, MD
-
副調査官:
- Joseph Pidala, MD
-
副調査官:
- Reshma Ramlal, MD
-
主任研究者:
- Sayeef Mirza, MD
-
副調査官:
- Alaa Ali, MD
-
副調査官:
- Deepakbabu Chellapanian, MD
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- First allogeneic HCT with peripheral blood as the only graft source used for allo HCT.
- Diagnosis of hematologic malignancy eligible for allo-HCT.
- Only patients with plan for post-transplant cyclophosphamide based GVHD prophylaxis are eligible.
- Eligible donors include matched-related, matched-unrelated, mismatched unrelated, and HLA-haploidentical relatives with a shared HLA haplotype with the patient, determined by high-resolution DNA typing at HLA-A, -B, -C, and -DRB1 loci per standardof care practice as documented in the medical record.
- Granulocyte-colony stimulating factor (G-CSF)-mobilized donor peripheral blood hematopoietic cells were targeted to a CD34+ cell dose of 5 × 106/kg with a minimum accepted dose of 2 × 106 cells per kg and a maximum dose of 10 × 106 cells per kg.
- Patient age ≥18 years at time of consent.
- Karnofsky performance status of ≥80% for the myeloablative and ≥60% for the nonmyeloablative (NMA) regimens.
- Patients with documented engraftment but require granulocyte-colony stimulating factor (G-CSF) to treat myelosuppression induced by drugs used to treat or prevent infection are eligible with G-CSF washout at least 14 days prior to Efineptakin Alfa.
- Participants must have adequate organ and marrow function
- Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- Absence of dyspnea or hypoxia (< 90% of saturation by pulse oximetry on room air).
- The effects of rh-IL-7 on the developing human fetus are unknown. For this reason and because immunomodulatory agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men treated or enrolled on this protocol must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for an additional four months after completion of the last study drug administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Progressive or advanced hematological malignancy.
- Patients with acute GVHD requiring systemic immunosuppression within the first 30 days (to avoid confounding lymphopenia from GVHD and steroid therapy). (Patients receiving GVHD prophylaxis will be allowed on this study).
- Patients who fail to achieve engraftment by day 30 post-HCT (for safety concerns, and due to major interventions including second HCT done in the setting of engraftment failure).
- History of Epstein-Barr virus (EBV) associated lymphoproliferation.
- Active uncontrolled viral, bacterial or fungal infection.
- History of autoimmune disease.
- Receiving systemic corticosteroid therapy (budesonide is allowed).
- Uncontrolled hypertension as defined by Systolic BP ≥ 160 mmHg or Diastolic BP ≥ 100 mmHg, confirmed by repeat measurement after appropriate rest.
- Corrected QT (QTcF) prolongation (QTcF > 470 ms) or prior history of significant arrhythmia or electrocardiogram (ECG) abnormalities.
- Presence of donor-specific antibodies.
- Inability or unwillingness to provide signed informed consent or comply with the study requirements.
- Participants who have not recovered from non-hematologic adverse events (AEs) due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1), with the exception of alopecia.
- Participants who are receiving any other investigational agents.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to rh-IL7 or other agents in the conditioning or GVHD prophylaxis regimen.
- Participants receiving any medications or substances that are prohibited while on study (see section 6.7.). As part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.
- Participants with psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant or nursing women will be excluded from this study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Efineptakin Alfa (rhIL-7-hyFc)
Participants will receive a single intramuscular dose of efineptakin alfa (NT-I7, rhIL-7-hyFc) on Day +60 after allogeneic hematopoietic cell transplantation. Dose assignment will follow a phase 1 dose-escalation design with dose levels of 240 μg/kg, 480 μg/kg, and 720 μg/kg. |
Single intramuscular administration on Day +60 after allo-HCT. Dose escalation includes 240 μg/kg, 480 μg/kg, and 720 μg/kg. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Recommended phase II dose (RP2D)
時間枠:Up to 90 days
|
Determine the recommended phase 2 dose (RP2D) of efineptakin alfa. |
Up to 90 days
|
|
Absolute Lymphocyte Count Recovery
時間枠:Up to 90 days
|
Proportion of participants achieving an absolute lymphocyte count (ALC) ≥1,000 cells/mm³ at Day +90 following transplantation. |
Up to 90 days
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Occurrence of infections
時間枠:Up to 100 days
|
Defined as developing (or experiencing re-activation) of a viral, bacterial, or fungal infection by Day +100. |
Up to 100 days
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Sayeef Mirza, MD、Moffitt Cancer Center
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- MCC-23978
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。